Saah Elna, Fadaei Payam, Gurkan Umut A, Sheehan Vivien
Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Department of Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, OH, USA.
Hematol Oncol Clin North Am. 2022 Dec;36(6):1077-1095. doi: 10.1016/j.hoc.2022.06.005.
One of the challenges in sickle cell disease is its clinical variability. Our ability to identify the complications that a patient is at risk for is limited by a lack of validated diagnostic and prognostic biomarkers. Clinical care is limited by a lack of diagnostics to capture the biological variability needed to precisely direct patient care. Many biomarkers have been proposed, but few validated. We must make a concerted effort as a field to rigorously test proposed biomarkers to improve outcomes for our patients.
镰状细胞病面临的挑战之一是其临床变异性。由于缺乏经过验证的诊断和预后生物标志物,我们识别患者所面临并发症风险的能力受到限制。临床护理也因缺乏诊断手段而受限,无法获取精确指导患者护理所需的生物学变异性信息。虽然已经提出了许多生物标志物,但经过验证的却很少。作为一个领域,我们必须共同努力,严格测试所提出的生物标志物,以改善我们患者的治疗效果。